ALBENDAZOLE



ALBENDAZOLE
            Albendazole, methyl[5-(propylthio)-1H-benzimi­dazol-2-yl] carbamate, is widely used for treating ruminant roundworms and flukes. The drug is available as an intraruminal bolus for ruminants.
ACTIVITY  Broad spectrum against a variety of nematodes, cestodes & protozoa; labeled for cattle & sheep (suspension only). Albendazole is active against all important nema­todes and their larvae, including hypobiotic or inhi­bited forms. It is also effective against tapeworms and adult fluke.
PHARMACOKINETICS
METABOLISM The drug is rapidly metabolized to the sulphone and sulphoxide which may provide the liver fluke and tapeworm activity. In sheep, 51% of the dose is excreted in the urine, mostly in the first 48 h. Very lit­tle albendazole remains unmetabolized. Drug residues persist for many days; consequently, a period of 10 days from dosing must elapse before sheep may be slaughtered (14 days for cattle) for meat, and cows producing milk for human consump­tion should not be treated.
            Pharmacokinetic data for albendazole in cattle, dogs and cats was not located. The drug is thought better absorbed orally than other benzimidazoles. Approximately 47% of an oral dose was recovered (as metabolites) in the urine over a 9-day period.
            After oral dosing in sheep, the parent compound was either not detectable or only transiently detectable in plasma due to a very rapid first-pass effect. The active metabolites, albendazole sulphoxide and albendazole sulfone, reached peak plasma concentrations 20 hours after dosing.
INDICATIONS Gastro-intestinal roundworms, lungworms, tapeworms, and adult Fasciola in cattle, sheep; Type II ostertagiosis; gastrointestinal roundworms and lungworms in goats and deer. Albendazole is labeled for the following endoparasites of cattle (not lactating): Ostertagia ostertagi, Haemonchus spp., Trichostrongylus spp., Nematodius spp., Cooperia spp., Bunostomum phlebotomum, Oesphagostomum spp., Dictacaulus vivaparus (adult and 4th stage larva), Fasciola hepatica (adults), and Moniezia spp.
            In sheep, albendazole is approved for treating the following endoparasites: Ostertagia circumcincta, Marshallagia marshalli, Haemonchus contortus, Trichostrongylus spp., Nematodius spp., Cooperia spp., Oesphagostomum spp., Chibertia ovina, Dictacaulus filaria, Fasciola hepatica, Fascioides magna, Moniezia expansa, and Thysanosoma actinoides.
            Albendazole is also used (extra-label) in small mammals, goats and swine for endoparasite control.
            In cats, albendazole has been used to treat Paragonimus kellicotti infections. In dogs and cats, albendazole has been used to treat capillariasis. In dogs, albendazole has been used to treat Filaroides infections. It has been used for treating giardia infections in small animals, but concerns about bone marrow toxicity have diminished enthusiasm for the drug’s use.
CONTRA-INDICATIONS  Concurrent administration of other ruminal boluses, treatment of ewes at a dosage of 7.5 mg/kg during the mating period and until 1 month after rams are removed. Contraindicated with hepatic failure, pregnancy, lactating dairy cattle. Do not use in pigeons, doves or crias.
WARNINGS Care not to exceed ‘fluke and worm dose’ in cows during first month of pregnancy; coughing for some weeks after treatment in cattle suffering from severe lung damage at time of treatment; operators should wear suitable protective clothing. The drug is not approved for use in lactating dairy cattle. The manufacturer recommends not administering to female cattle during the first 45 days of pregnancy or for 45 days after removal of bulls. In sheep, it should not be administered to ewes during the first 30 days of pregnancy or for 30 days after removal of rams.
            Pigeons and doves may be susceptible to albendazole and fenbendazole toxicity (intestinal crypt epithelial necrosis and bone marrow hypoplasia). Nine alpaca crias receiving albendazole at dosages from 33 – 100 mg/kg/day once daily for 4 consecutive days developed neutropenia and severe watery diarrhea. All required treatment and 7 of 9 animals treated died or were euthanized secondary to sepsis or multiple organ failure (Gruntman and Nolen-Walston 2006). In humans, caution is recommended for use in patients with liver or hematologic diseases. Albendazole was implicated as being an oncogen in 1984, but subsequent studies were unable to demonstrate any oncogenic or carcinogenic activity of the drug.
TOXICITY
            The safety index has been reported to be 7.5-20 times the recommended dose. High doses may be embryotoxic. May cause GI effects (including hepatic dysfunction) & rarely blood dyscrasias (aplastic anemia).
ADVERSE EFFECTS
            Albendazole is tolerated without significant adverse effects when dosed in cattle or sheep at recommended dosages. Dogs treated at 50 mg/kg twice daily may develop anorexia. Cats may exhibit clinical signs of mild lethargy, depression, anorexia, and resistance to receiving the medication when albendazole is used to treat Paragonimus. Albendazole has been implicated in causing aplastic anemia in dogs, cats, and humans.
REPRODUCTIVE/NURSING SAFETY
            Albendazole has been associated with teratogenic and embryotoxic effects in rats, rabbits and sheep when given early in pregnancy. The manufacturer recommends not administering to female cattle during the first 45 days of pregnancy or for 45 days after removal of bulls. In sheep, it should not be administered to ewes during the first 30 days of pregnancy or for 30 days after removal of rams. In humans, the FDA categorizes this drug as category C for use during pregnancy (Animal studies have shown an adverse effect on the fetus, but there are no adequate studies in humans; or there are no animal reproduction studies and no adequate studies in humans.)
            Safety during nursing has not been established.
OVERDOSAGE/TOXICITY
            Doses of 300 mg/kg (30X recommended) and 200 mg/kg (20X) have caused death in cattle and sheep, respectively. Doses of 45 mg/kg (4.5X those recommended) did not cause any adverse effects in cattle tested. Cats receiving 100 mg/kg/day for 14 – 21 days showed signs of weight loss, neutropenia and mental dullness.
DRUG INTERACTIONS
            The following drug interactions have either been reported or are theoretical in humans or animals receiving albendazole and may be of significance in veterinary patients:
            CIMETIDINE: Increased albendazole levels in bile and cystic fluid
            DEXAMETHASONE: May increase albendazole serum levels
            PRAZIQUANTEL: May increase albendazole serum levels
DOSAGE By mouth
CATTLE:                     roundworms and tapeworms, 7.5 mg/kg
                                    Adult flukes, roundworms, and tapeworms, 10 mg/kg
For susceptible parasites:
            a) 10 mg/kg PO
            b) 7.5 mg/kg PO; 15 mg/kg PO for adult liver flukes
            c) For adult liver flukes: 10 mg/kg PO; best used in fall when the majority are adults (little or no efficacy against immature forms). A second treatment in winter may be beneficial.
            d) For gastrointestinal cestodes: 10 mg/kg PO
SHEEP:                       roundworms and tapeworms, 5 mg/kg
                                    Adult flukes, roundworms, and tapeworms, 7.5 mg/kg
GOATS, DEER:           roundworms, 10 mg/kg
SHEEP & GOATS:
                        For susceptible parasites:
            a) 7.5 mg/kg PO (0.75 mL of the suspension per 25 lb. body weight).
            b) 7.5 mg/kg PO; 15 mg/kg PO for adult liver flukes
            c) For adult liver flukes in sheep: 7.6 mg/kg
            d) For treatment of nematodes in sheep: 3 mL of suspension per 100 lbs of body weight PO
HORSES:                    5 mg/kg.
SWINE:
                        For susceptible parasites:
            a) 5 – 10 mg/kg PO
DOGS:
                        For Filaroides hirthi infections:
            a) 50 mg/kg q12h PO for 5 days; repeat in 21 days. Clinical signs may suddenly worsen during therapy, presumably due to a reaction to worm death.
            b) 25 mg/kg PO q12h for 5 days; may repeat in 2 weeks (also for Oslerus osleri)                  For Filaroides osleri (also known as Oslerus osleri) infections:
            a) 9.5 mg/kg for 55 days or 25 mg/kg PO twice daily for 5 days. Repeat therapy in 2 weeks.
                        For Capillaria plica:
            a) 50 mg/kg q12h for 10 – 14 days. May cause anorexia.
                        For Paragonimus kellicotti:
            a) 50 mg/kg PO per day for 21 days
            b) 30 mg/kg once daily for 12 days
            c) 25 mg/kg PO q12h for 14 days
                        For Giardia:
            a) 25 mg/kg PO q12h for 4 doses
            b) 25 mg/kg PO twice daily for 5 days
            c) 25 mg/kg PO twice daily for 2 – 5 days
                        For Leishmaniasis:
            a) 10 mg/kg PO once daily for 30 days or 5 mg/kg PO q6h for 60 days
            CATS:
                        For Paragonimus kellicotti:
            a) 50 mg/kg PO per day for 21 days
            b) 25 mg/kg PO q12h for 10 – 21 days
            c) 30 mg/kg once a day for 6 days
            d) 25 mg/kg PO q12h for 14 days
                        For Giardia:
            a) 25 mg/kg PO twice daily for 5 days
            b) 25 mg/kg PO q12h for 3 – 5 days; may cause bone marrow suppression in dogs and cats.
                        For treatment of liver flukes (Platynosum or Opisthorchiidae families):
            a) 50 mg/kg PO once daily until ova are gone
            RABBITS/RODENTS/SMALL MAMMALS:
            a) Rabbits:
            For Encephalitozoon phacoclastic uveitis: 30 mg/kg PO once daily for 30 days, then 15 mg/kg PO once daily for 30 days
            b) Chinchillas: For Giardia: 50 – 100 mg/kg PO once a day for 3 days
BIRDS:
            a) Ratites: Using the suspension: 1 mL/22 kg of body weight twice daily for 3 days; repeat in 2 weeks. Has efficacy against flagellate parasites and tapeworms.
Monitoring
            Efficacy
                        Adverse effects if used in non-approved species or at dosages higher than recommended
                        Consider monitoring CBC’s and liver enzymes (q4 – 6 weeks) if treating long-term (>1 month)
Note. For therapeutic purposes albendazole and albendazole oxide may be considered equivalent in effect.

Comments

Popular posts from this blog

Pharmacokinetics - Drug absorption and Transport of drugs across biological membranes

Skeletal muscle relaxants

PHARMACOGNOSY - SOURCES AND COMPOSITION OF DRUGS